NeuroPace Yönetim
Yönetim kriter kontrolleri 3/4
NeuroPace CEO'su Joel Becker, Jul2023 tarihinde atandı, in görev süresi 2.92 yıldır. in toplam yıllık tazminatı $ 2.41M olup, şirket hissesi ve opsiyonları dahil olmak üzere 23.6% maaş ve 76.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.41% ine doğrudan sahiptir ve bu hisseler $ 2.20M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.5 yıl ve 4.9 yıldır.
Anahtar bilgiler
Joel Becker
İcra Kurulu Başkanı
US$2.4m
Toplam tazminat
| CEO maaş yüzdesi | 23.56% |
| CEO görev süresi | 2.9yrs |
| CEO sahipliği | 0.4% |
| Yönetim ortalama görev süresi | 1.5yrs |
| Yönetim Kurulu ortalama görev süresi | 4.9yrs |
Son yönetim güncellemeleri
Recent updates
Anlatı Güncellemesi • Jun 02
NPCE: Strong Prescriber Momentum And 2026 Guidance Will Support More Optimistic Outlook
Narrative Update on NeuroPace The analyst price target for NeuroPace has moved from $19 to $20. Analysts point to stronger prescriber and patient pipeline trends and higher 2026 revenue guidance for the core RNS business as key drivers of this change.Analiz Makalesi • May 15
NeuroPace, Inc. (NASDAQ:NPCE) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
It's been a sad week for NeuroPace, Inc. ( NASDAQ:NPCE ), who've watched their investment drop 18% to US$15.79 in the...
Anlatı Güncellemesi • Apr 30
NPCE: Future Returns Will Reflect Trial Data Strength And Execution Risk
Analysts have lifted their price target on NeuroPace from $15.63 to $18.00, citing updated expectations for revenue growth and profit margins, as well as a higher future P/E multiple following recent Street research coverage. Analyst Commentary The latest Street research on NeuroPace reflects constructive top line expectations alongside a watchful stance on execution and valuation risk.
Anlatı Güncellemesi • Apr 15
NPCE: Refreshed Growth Assumptions And Richer P E Outlook Will Support Upside
Analysts have increased their average price target on NeuroPace by $1, citing updated assumptions that include slightly stronger revenue growth, a revised discount rate, a lower projected profit margin and a higher future P/E multiple. Analyst Commentary Bullish analysts are highlighting NeuroPace as a name where recent research work has led to more constructive views on both execution and valuation.Anlatı Güncellemesi • Apr 01
NPCE: Higher Margin Conviction And Reaffirmed Guidance Will Support More Optimistic Outlook
Analysts have modestly increased their price target on NeuroPace by $1, citing refreshed assumptions around long term profit margins and a slightly higher future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts see room for long term margin improvement, which supports their willingness to apply a slightly higher future P/E multiple in their models.Anlatı Güncellemesi • Mar 17
NPCE: Expanded Epilepsy Indication And Guidance Reaffirmation Will Support More Optimistic Outlook
Analysts increased their price target on NeuroPace by about $0.45 to $19.88, citing updated assumptions around revenue growth, profit margins, the discount rate, and future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts view the higher price target of about $19.88 as better aligned with their revised expectations for revenue growth and margin progress in the current model.Anlatı Güncellemesi • Mar 03
NPCE: Refined Risk And Margin Outlook Will Support Future Upside Potential
Analysts lifted their price target on NeuroPace by $1, citing updated assumptions around the discount rate, profit margin, and future P/E that refine how they view the company’s risk and earnings potential. Analyst Commentary Recent Street research points to a more constructive tone around NeuroPace, with bullish analysts fine tuning their models rather than making wholesale changes.Anlatı Güncellemesi • Feb 17
NPCE: Future Returns Will Reflect Trial Data Strength And Execution Risk
Analysts have raised their price target for NeuroPace by about $1 to approximately $16, reflecting updated assumptions around revenue growth, profit margins, and a lower future P/E multiple. Analyst Commentary Even with the roughly $1 move in the price target to about $16, some research commentary still reads as cautious rather than outright bullish.Anlatı Güncellemesi • Feb 03
NPCE: Updated Seizure Trial Data Will Support A More Optimistic Outlook
Analysts have nudged their price target on NeuroPace higher to about US$19.43 from roughly US$17.13, citing updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E that are consistent with recent Street research. Analyst Commentary Analysts updating their models around NeuroPace are using the revised price target to reflect refreshed assumptions on valuation, growth expectations, and execution risks rather than a wholesale change in thesis.Anlatı Güncellemesi • Jan 20
NPCE: Broader Epilepsy Indication And Trial Evidence Will Support Future Upside
Analysts now see NeuroPace as fairly valued around US$22.00 per share. They have made only slight tweaks to assumptions for discount rate, revenue growth, profit margin and future P/E, refining rather than overhauling their previous price target view.Analiz Makalesi • Jan 09
NeuroPace (NASDAQ:NPCE) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Anlatı Güncellemesi • Jan 06
NPCE: Expanded Epilepsy Indication And Trial Data Will Support Bullish Outlook
Analysts lifted their price target on NeuroPace from US$20.00 to US$22.00, citing changes in their fair value estimate along with updated assumptions for discount rate, revenue growth, profit margin and future P/E. What's in the News NeuroPace filed a Premarket Approval Supplement with the U.S. FDA to expand the labeled indication for its RNS System to antiseizure medication resistant idiopathic generalized epilepsy with generalized tonic clonic seizures, supported by preliminary NAUTILUS trial data showing a 77% median reduction in GTC seizures at 18 months and a favorable safety profile.Anlatı Güncellemesi • Dec 15
NPCE: Future Performance Will Reflect Trial Data Strength And Moderate Risk
Analysts have raised their price target on NeuroPace from 13.00 dollars to 15.00 dollars. This reflects modestly lower perceived risk, slightly stronger long term margin potential, and still supportive valuation multiples despite a tempered revenue growth outlook.Analiz Makalesi • Nov 19
Revenues Tell The Story For NeuroPace, Inc. (NASDAQ:NPCE) As Its Stock Soars 25%
Despite an already strong run, NeuroPace, Inc. ( NASDAQ:NPCE ) shares have been powering on, with a gain of 25% in the...Analiz Makalesi • Sep 19
NeuroPace, Inc. (NASDAQ:NPCE) Looks Just Right With A 25% Price Jump
Those holding NeuroPace, Inc. ( NASDAQ:NPCE ) shares would be relieved that the share price has rebounded 25% in the...Analiz Makalesi • Aug 14
NeuroPace, Inc. (NASDAQ:NPCE) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
NasdaqGM:NPCE 1 Year Share Price vs Fair Value Explore NeuroPace's Fair Values from the Community and select yours...Seeking Alpha • Jun 29
NeuroPace: Volatile, Uncertain, But Promising
Summary NeuroPace has shown strong sales growth in its core drug-resistant epilepsy market, but remains unprofitable due to ongoing R&D expenses. Recent topline momentum is impressive, with 2024 guidance raised and sales growth accelerating, yet operating losses have stopped narrowing and even increased. The NAUTILUS trial failed to meet primary endpoints for generalized epilepsy, a major setback that limits near-term market expansion potential. Despite a reasonable sales multiple and recent financing, the failed trial and persistent losses make me cautious and hesitant to increase my position. Read the full article on Seeking AlphaAnaliz Makalesi • Jun 19
Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • May 13
NeuroPace, Inc. (NASDAQ:NPCE) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
NeuroPace, Inc. ( NASDAQ:NPCE ) shareholders would be excited to see that the share price has had a great month...
Yeni Anlatı • Mar 30
Expanding Level 4 Epilepsy Centers Will Unlock Future Potential
Expanding presence in epilepsy centers and Project CARE may significantly boost revenue by increasing market penetration and service delivery.Analiz Makalesi • Mar 07
NeuroPace, Inc. (NASDAQ:NPCE) Annual Results: Here's What Analysts Are Forecasting For This Year
It's been a sad week for NeuroPace, Inc. ( NASDAQ:NPCE ), who've watched their investment drop 11% to US$11.18 in the...Analiz Makalesi • Jan 24
NeuroPace, Inc. (NASDAQ:NPCE) Looks Just Right With A 26% Price Jump
Despite an already strong run, NeuroPace, Inc. ( NASDAQ:NPCE ) shares have been powering on, with a gain of 26% in the...Analiz Makalesi • Dec 04
After Leaping 90% NeuroPace, Inc. (NASDAQ:NPCE) Shares Are Not Flying Under The Radar
NeuroPace, Inc. ( NASDAQ:NPCE ) shares have had a really impressive month, gaining 90% after a shaky period beforehand...Analiz Makalesi • Nov 14
Here's What Analysts Are Forecasting For NeuroPace, Inc. (NASDAQ:NPCE) After Its Third-Quarter Results
A week ago, NeuroPace, Inc. ( NASDAQ:NPCE ) came out with a strong set of quarterly numbers that could potentially lead...Analiz Makalesi • Nov 07
Does NeuroPace (NASDAQ:NPCE) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Aug 03
NeuroPace, Inc. (NASDAQ:NPCE) Screens Well But There Might Be A Catch
It's not a stretch to say that NeuroPace, Inc.'s ( NASDAQ:NPCE ) price-to-sales (or "P/S") ratio of 2.9x right now...Analiz Makalesi • Apr 12
Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Feb 25
NeuroPace: Picking Up The Pace
Summary NeuroPace shares have doubled since September 2023, driven by strong operating momentum. The company aims to improve the lives of epilepsy patients with its remote monitoring system, which has the potential for significant growth. Following the share price rally, I have trimmed my position but continue to hold a long position due to the company's potential and operating momentum. Read the full article on Seeking AlphaAnaliz Makalesi • Jan 22
Why Investors Shouldn't Be Surprised By NeuroPace, Inc.'s (NASDAQ:NPCE) 58% Share Price Surge
Despite an already strong run, NeuroPace, Inc. ( NASDAQ:NPCE ) shares have been powering on, with a gain of 58% in the...Analiz Makalesi • Apr 17
NeuroPace, Inc. (NASDAQ:NPCE) Stock Rockets 39% But Many Are Still Ignoring The Company
NeuroPace, Inc. ( NASDAQ:NPCE ) shares have continued their recent momentum with a 39% gain in the last month alone...CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$22m |
| Dec 31 2025 | US$2m | US$568k | -US$21m |
| Sep 30 2025 | n/a | n/a | -US$24m |
| Jun 30 2025 | n/a | n/a | -US$26m |
| Mar 31 2025 | n/a | n/a | -US$25m |
| Dec 31 2024 | US$3m | US$529k | -US$27m |
| Sep 30 2024 | n/a | n/a | -US$28m |
| Jun 30 2024 | n/a | n/a | -US$30m |
| Mar 31 2024 | n/a | n/a | -US$32m |
| Dec 31 2023 | US$2m | US$248k | -US$33m |
Tazminat ve Piyasa: Joel 'ın toplam tazminatı ($USD 2.41M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 2.63M ).
Tazminat ve Kazançlar: Joel 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Joel Becker (58 yo)
2.9yrs
Görev süresi
US$2,408,567
Tazminat
Mr. Joel D. Becker serves as CEO & Director of at NeuroPace, Inc. since July 10, 2023 and serves as its President. He had been President of Cardiac Rhythm Management & Neuromodulation at Integer Holdings C...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, President & Director | 2.9yrs | US$2.41m | 0.41% $ 2.2m | |
| Chief Financial Officer | 1yr | US$1.88m | Veri yok | |
| Chief Medical Officer | 21.9yrs | US$1.03m | 0.15% $ 818.8k | |
| Advisor | 1yr | US$846.31k | 0.23% $ 1.3m | |
| Chief of Operations & Development | 2.1yrs | Veri yok | Veri yok | |
| Head of Investor Relations | no data | Veri yok | Veri yok | |
| General Counsel & Corporate Secretary | 2.2yrs | Veri yok | Veri yok | |
| Vice President of Marketing | 1.4yrs | Veri yok | Veri yok | |
| Senior Vice President of Sales | 1.1yrs | Veri yok | Veri yok | |
| Vice President of Human Resources | 1.7yrs | Veri yok | Veri yok | |
| VP & Controller | less than a year | Veri yok | Veri yok |
1.5yrs
Ortalama Görev Süresi
61.5yo
Ortalama Yaş
Deneyimli Yönetim: NPCE 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.5 yıl), bu da yeni bir ekibin varlığını gösteriyor.
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO, President & Director | 2.9yrs | US$2.41m | 0.41% $ 2.2m | |
| Independent Director | 29.4yrs | US$123.70k | 1.07% $ 5.7m | |
| Chairman of the Board | 28.6yrs | US$173.70k | 1.75% $ 9.3m | |
| Independent Director | 3.4yrs | US$126.20k | 0.044% $ 232.2k | |
| Independent Director | 1.4yrs | US$257.20k | 0.0085% $ 45.2k | |
| Independent Director | 13.4yrs | US$136.20k | 0.12% $ 643.5k | |
| Board Observer | no data | Veri yok | Veri yok | |
| Independent Director | 4.6yrs | US$138.70k | 0.0085% $ 45.2k | |
| Independent Director | 5.2yrs | US$138.70k | 0.065% $ 344.6k |
4.9yrs
Ortalama Görev Süresi
58yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: NPCE 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.9 yıldır).
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/09 08:39 |
| Gün Sonu Hisse Fiyatı | 2026/06/09 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
NeuroPace, Inc. 13 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Michael Polark | Baird |
| Sarah James | Cantor Fitzgerald & Co. |
| Ross Osborn | Cantor Fitzgerald & Co. |